Catalyst Wire Dossier Catalyst Wire Dossier

Bempikibart

· Q32 Bio Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bempikibart, covering 2025-10-31 to 2025-10-31. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) [Phase 2]

See pricing